Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.

CANCER drug co. Oxford Biomedica charts (OXB)     

apple - 25 Mar 2004 20:47

Chart.aspx?Provider=EODIntra&Code=OXB&Sidraw?scheme=Colourful&size=Medium&showVodraw?scheme=Colourful&showVolume=true&stdraw?scheme=Colourful&size=Medium&showVoChart.aspx?Provider=EODIntra&Code=OXB&SiChart.aspx?Provider=EODIntra&Code=OXB&Sidraw?scheme=Designer&size=Big&showVolumedraw?scheme=Designer&size=Big&showVolume


OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021


lex1000 - 01 Mar 2006 23:59 - 890 of 1451

http://www.britishbulls.com/StockPage.asp?CompanyTicker=OXB&MarketTicker=HEALTH%20CARE&Typ=S


OXB

Oxford BioMedica PLC
Daily Commentary


Our system posted a BUY CONFIRMED today. The previous SELL recommendation that was confirmed was made on 20.02.2006 (9) days ago, when the stock price was 31.2500. Since then OXB has gained 0.00% .

Were you eager to go long? Well, without doubt, it was the right time to do so. The BUY signal was finally confirmed, and most probably you have called your broker and placed your long orders with no hesitation.

Don't worry if you have missed this buying opportunity. The market may now give you a second chance. You may still find good prices for buying in the next session.

[MOTTO OF THE DAY]
Buying was right in a nice bullish day
Hold your stocks now whatever they say



BUY
CONFIRMED


31.250
+0.2500 +0.81%

Candlestick Analysis

Todays Candlestick Patterns:

Short White Candlestick

Today a Short White Candlestick was formed. This represents relatively weak buying pressure with little price movement.

queen1 - 13 Apr 2006 14:07 - 891 of 1451

It's been a long time since anyone's had anything to say about OXB. I'm assuming the lack of interest and southwards drift of the sp is down to the lack of newsflow?

Oakapples142 - 13 Apr 2006 14:14 - 892 of 1451


I think it is one of those stocks which we quietly support for two good reasons - a major cancer breakthrough and as a result of that - a nice little earner

queen1 - 13 Apr 2006 19:37 - 893 of 1451

True. But will it be 2006 or 2066?!!

Oakapples142 - 19 Apr 2006 16:14 - 894 of 1451


So what do we read into "someone" selling over 11 mil to-day and the SP rises 7%

queen1 - 19 Apr 2006 18:44 - 895 of 1451

I have no idea but if they fancy selling 11 mil agan tomorrow we'll be back over 30p!

KEAYDIAN - 20 May 2006 13:35 - 896 of 1451

Gene therapy group Oxford BioMedica said it had received a Special Protocol Assessment agreement from the FDA. The agreement was made for a phase III trial of TroVax, its renal cell carcinoma treatment and paves the way for the start of the trial in the second of this year. Meanwhile, discussions are ongoing with regards to trials in Europe. The shares ended the final session of the week 1.25p lower at 29.25p.

KD.

movinup - 22 May 2006 12:06 - 897 of 1451

anyone bought rgt, news looks good

Ultimate Cynic - 24 May 2006 10:30 - 898 of 1451

OAK -It's probably EVO manipulating the SP.

robstuff - 18 Jun 2006 23:43 - 899 of 1451

Expect some huge buying of OXB at this price, it's been the target for the institutions to trade back to 35-40 and starts here, a licence deal is around the corner and there is at least one large Pharmaceutical co eyeing them up. Trial in Europe will also be announced shortly...

queen1 - 19 Jun 2006 19:27 - 900 of 1451

I certainly hope so robstuff. I've tucked these away for the best part of 3 years now and it's been depressing to see them meander back to the price I bought them at but I still believe so I hope you're right!

robstuff - 26 Jun 2006 12:56 - 901 of 1451

More excellent news - overlooked by the market but adds value.

queen1 - 02 Aug 2006 13:44 - 902 of 1451

Broadly positive news released on Monday. I guess the second part of the message may account for the recent decline in sp but there appear to be a number of irons in the fire regarding a potential partner which bodes well going forward:

Oxford, UK - 31 July 2006: Oxford BioMedica today issues an update on TroVax, the Company's leading cancer immunotherapy product. The update provides information on progress with clinical trial programmes and a marketing partner deal for TroVax.

The Board is pleased to confirm that the TroVax clinical development plan is on
track with appropriate regulatory submissions being made and trial centres for
the phase III TRIST study being set up in the US and Western and Eastern Europe.
Other product development programmes are also progressing according to plan. A
full update will be given with the Company's interim results on 5 September 2006.

A number of shareholders have asked for information on progress towards a TroVax
deal. The Company is in active discussions with a number of potential commercial
partners for TroVax. Inevitably those discussions are highly sensitive. All the
potential partners are substantial companies and have the capability to support
the Company's plans for TroVax and the successful marketing of this product.

Clarification as regards Therion Biologics

The Company has noted some speculation in the market that the failure of
clinical trials of PANVAC-VF, developed by the privately owned United States
company, Therion Biologics, might suggest that phase III trials of TroVax will
not be successful.


Although the Directors do not have access to detailed information on the
PANVAC-VF study, they wish to make the following comments:

While PANVAC-VF uses a similar viral delivery system to TroVax, the active
antigenic components of TroVax are completely different to those used in
PANVAC-VF. PANVAC-VF comprises CEA and Muc-1 whereas TroVax comprises the Company's proprietary antigen, 5T4.
The PANVAC-VF phase III study was in pancreatic cancer patients who had
already failed chemotherapy. This is a particularly challenging target where
no product has shown a survival benefit. In the case of a vaccine the
problem is that the patients' disease advances significantly before a strong
immune response has time to be established by the product. The planned
TroVax phase III TRIST trial is in advanced renal cell cancer patients who
will have received no prior therapy for their metastatic disease and who
have a median survival, with current care, of about 12 months. As has been
shown in a number of phase I/II and phase II studies of TroVax, this is
ample time for an immune response to be established.

In summary, the Directors do not believe that data from the PANVAC-VF trial have
a significant bearing on the future of TroVax.

Oakapples142 - 22 Aug 2006 12:53 - 903 of 1451


Good daily movement upwards - anyone have an opinion as to why?

One2Watch - 22 Aug 2006 13:17 - 904 of 1451

Oxford BioMedica expects to commence patient recruitment in its Phase III trial in RCC, designated as TRIST (TroVax Renal Immunotherapy Survival Trial), during the second half of 2006. Oxford BioMedica has a Special Protocol Assessment agreement from the US Food and Drug Administration for the TRIST study. Further trials are also planned in colorectal cancer and other cancer types.

Taken from : Oxford Bio's website

http://www.oxfordbiomedica.co.uk/news/2006-ob-17.htm

Oakapples142 - 22 Aug 2006 13:43 - 905 of 1451


Thanks - you too are "One2Watch" !!

hangon - 04 Sep 2006 12:37 - 906 of 1451

Just this last week we hear a great story where a father survived cancer and saw his daughter married. Great story and it was down to gene-therapy.
All good so far.
However, this has pushed up the price of OXB - yippee!
Except it was nothing to do with OXB - and importantly the "news" was almost a year old - the guy survived and his daughter is already married......so I fail to understand why the market is suddenly excited - sure it gives some credence to gene-therapy......well, except in the trial 80% of the patients died.....this guy and (I think one other survived - buit that's part of the mystery ).
Maybe he has just died but the "human-interest" story is being touted to gain funding for the US-university-labs. It's very odd...Why now?
Why wasn't this story on the newswire when the daughter got married in September 2005? That's what's really odd.
So, Dunno, but it ain't OXB
(Indeed one might think that this shows there is likely to be competition in the prime market....oh dear.)...and their news is a year (at least) ahead. I hold

PARKIN - 04 Sep 2006 17:11 - 907 of 1451

from what I remeber it was also on the news on Channel 4 on Friday evening.

Oakapples142 - 04 Sep 2006 19:19 - 908 of 1451


I think you will find that there has/is/will be a presentation in USA although no RNS as yet

robstuff - 04 Sep 2006 21:56 - 909 of 1451

they used OXBs technology to deliver the protein to the cells, this is the reason for the news to affect OXB
Register now or login to post to this thread.